AtriCure, Inc. (ATRC)
NasdaqGM · Medical Instruments & Supplies
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
AtriCure, Inc. is trading at $45.92, up 2.57% on the session. The 50 day average sits at $33.79 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 76.7, which reads as overbought, and MACD is bullish crossover. Volume is below average.
The nearest support is around $37.44 with resistance near $44.48, so that band frames the current range. Average daily movement is roughly $1.64, or about 3.6% of the share price, which is what any stop placement has to allow for. The overall health score of 67 out of 100 combines a trend score of 75, momentum of 78 and a risk score of 38.
Technical indicators
About AtriCure, Inc.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Company website